Lampalizumab(Lampalizumab) - 药物靶点：CFD_专利_临床

概要

基本信息

药物类型

Fab片段抗体

别名

Anti-complement Factor D antibody、Anti-factor D、Lampalizumab (USAN/INN)

+ [7]

靶点

CFD

作用方式

抑制剂

作用机制

CFD抑制剂(补体因子D抑制剂)

治疗领域

遗传病与畸形眼部疾病

在研适应症-

非在研适应症

年龄相关性黄斑变性地图样萎缩

原研机构

Genentech, Inc.

在研机构-

非在研机构

Hoffmann-La Roche, Inc.

权益机构-

最高研发阶段终止临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 208556L

来源: *****

Sequence Code 208562H

来源: *****

关联

9

项与 Lampalizumab 相关的临床试验

NCT02745119

/ Terminated临床3期

A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study

This multicenter open-label extension study is designed to evaluate the safety and tolerability of lampalizumab intravitreal injections in participants with GA secondary to age-related macular degeneration (AMD) who completed 96 weeks of treatment in Studies GX29176 (NCT02247479) or GX29185 (NCT02247531). The extension will enroll participants from the parent studies who received investigational lampalizumab, as well as lampalizumab-naive participants exposed to sham comparator. All participants will receive open-label lampalizumab in the present study.

开始日期2016-07-21

申办/合作机构

Hoffmann-La Roche, Inc.

PER-003-15

/ Suspended临床3期

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTEREDINTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION

开始日期2015-08-01

申办/合作机构-

PER-076-14

/ Suspended临床3期

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTEREDINTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION

开始日期2015-07-06

申办/合作机构-

100 项与 Lampalizumab 相关的临床结果

登录后查看更多信息

100 项与 Lampalizumab 相关的转化医学

登录后查看更多信息

100 项与 Lampalizumab 相关的专利（医药）

登录后查看更多信息

37

项与 Lampalizumab 相关的文献（医药）

2025-05-01·Ophthalmology science

Reading Performance in Geographic Atrophy: Comparison of Different Reading Speed Measures for Capturing Longitudinal Changes

Article

作者: Steffen, Verena ; Wu, Zhichao ; Guymer, Robyn H ; Harris, Will ; Cukras, Catherine A ; Ferrara, Daniela

Purpose:

To compare different reading speed measures for capturing longitudinal visual function changes in eyes with geographic atrophy (GA) secondary to age-related macular degeneration.

Design:

Analysis of data from Chroma (NCT02247479) and Spectri (NCT02247531), 2 identically designed, phase III, double-masked, randomized controlled clinical trials for lampalizumab.

Participants:

Nine hundred forty participants aged ≥50 years old with bilateral GA, who completed monocular testing of reading speed at ≥3 visits over >1-year follow-up.

Methods:

Monocular reading speed was assessed using the Minnesota Low-Vision Reading Test (MNRead). Four different reading speed measures were derived and compared: reading speed of the fastest sentence read (RS₁), mean reading speed of the 3 fastest sentences read (RS₂), mean reading speed of the sentences larger than the critical print size (RS₃), and mean reading speed of the 10 largest print sizes (termed the Reading Accessibility Index [ACC]).

Main Outcome Measures:

Coefficient of variation (CV), with lower values reflecting better performance of a measure for capturing longitudinal change relative to interindividual variability.

Results:

All 4 reading speed measures showed a significant decline at 48, 72, and 96 weeks from baseline (P < 0.001 for all). The CVs for ACC and RS₂ (204% and 208%, respectively) were lower than for RS₁ (255%; P ≤ 0.002) and RS₃ (224%; P ≥ 0.068) for detecting change from baseline at 48 weeks, but these 2 measures were not significantly different from each other (P = 0.362). There were also statistically significant, but weak, negative correlations between the change from baseline at 48 weeks for all 4 reading speed measures with GA area on fundus autofluorescence imaging (ρ = -0.13 to -0.15; all P < 0.001).

Conclusions:

The mean reading speed derived from either the 10 print sizes found in everyday life (ACC) or the fastest 3 sentences read (RS₂) was better than 2 widely used measures (RS₁ and RS₃) at capturing progressive functional decline in eyes with GA and may be the preferred measures in future clinical trials and studies. All reading speed measures also showed an expected progressive decline over time, but they only showed a weak correlation with GA growth.

Financial Disclosures:

Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

2025-04-01·OPHTHALMOLOGY

Visual Loss in Geographic Atrophy

Article

作者: Tufail, Adnan ; Schmitz-Valckenberg, Steffen ; Csaky, Karl ; Sadda, Srinivas R ; Chakravarthy, Usha ; Kaiser, Peter K. ; Steffen, Verena ; Lad, Eleonora M. ; Kaiser, Peter K ; Sadda, Srinivas R. ; Ferrara, Daniela ; Lad, Eleonora M ; Anegondi, Neha

PURPOSE:

To assess the correlation of lesion growth rate and baseline factors, including foveal involvement and focality, on visual loss as measured by best-corrected visual acuity (BCVA) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

DESIGN:

Retrospective analysis of the lampalizumab phase 3 (NCT02247479 and NCT02247531) and prospective observational (NCT02479386) trials.

PARTICIPANTS:

Patients with bilateral GA.

METHODS:

Monthly BCVA and fundus autofluorescence (FAF) at baseline and every 6 months for 2 years were analyzed. Baseline GA area from FAF images was correlated to baseline BCVA and change in BCVA. The lesion growth rate was calculated as the slope of a linear fit from all available GA area measurements of a patient. The association between GA growth rate quartiles and BCVA changes was assessed, subgrouped by GA foveal involvement or focality. Time-to-event analysis for BCVA loss of ≥5, ≥10, and ≥15 letters was performed. A Cox regression model adjusted for baseline factors was performed on these outcomes. Kaplan-Meier curves are provided for each baseline factor and GA growth rate.

MAIN OUTCOME MEASURES:

Correlations of baseline BCVA, GA area, and growth rate with change in BCVA, and time to ≥5, ≥10, and ≥15-letter loss by foveal involvement or focality.

RESULTS:

Best-corrected visual acuity and GA area at baseline did not correlate with BCVA change at any visit. Geographic atrophy growth rate showed a weak correlation with BCVA loss, which increased over time. The 2 highest GA growth rate quartiles had accelerated BCVA loss in eyes with subfoveal, unifocal lesions. Approximately 75%, 50%, and 25% of study eyes experienced a ≥5-, ≥10-, and ≥15-letter loss by 2 years, respectively.

CONCLUSIONS:

Best-corrected visual acuity and GA area at baseline did not correlate with BCVA loss, but faster GA growth rates appeared to be associated with faster BCVA loss. Geographic atrophy foveal involvement and focality correlated with the rate of BCVA loss with subfoveal lesions at high risk of vision loss over time, especially when the GA lesion was unifocal.

FINANCIAL DISCLOSURE(S):

Proprietary or commercial disclosure may be found after the references.

2025-03-01·Ophthalmology science

Deep Learning to Predict the Future Growth of Geographic Atrophy from Fundus Autofluorescence

Article

作者: Yang, Qi ; Ferrara, Daniela ; Schiffman, Courtney ; Holz, Frank G ; Salvi, Anish ; Sadda, Srinivas R ; Cluceru, Julia ; Anegondi, Neha ; Rabe, Christina ; Lee, Aaron Y ; Keane, Pearse A ; Gao, Simon S

Purpose:

The region of growth (ROG) of geographic atrophy (GA) throughout the macular area has an impact on visual outcomes. Here, we developed multiple deep learning models to predict the 1-year ROG of GA lesions using fundus autofluorescence (FAF) images.

Design:

In this retrospective analysis, 3 types of models were developed using FAF images collected 6 months after baseline to predict the GA lesion area (segmented lesion mask) at 1.5 years, FAF images collected at baseline and 6 months to predict the GA lesion at 1.5 years, and FAF images collected 6 months after baseline to predict the GA lesion at 1 and 1.5 years. The 1-year ROG from the 6-month visit was derived by taking the difference between the GA lesion area (segmented lesion mask) at the 1.5-year and 6-month visits.

Participants:

Patients enrolled in the following lampalizumab clinical trials and prospective observational studies: NCT02247479, NCT02247531, NCT02479386, and NCT02399072.

Methods:

Datasets of study eyes from 597 patients were split into model training (310), validation (78), and test sets (209), stratified by baseline or initial lesion area, lesion growth rate, foveal involvement, and focality. Deep learning experiments were performed using the 2-dimensional U-Net; whole-lesion and multiclass models were developed.

Main Outcome Measures:

The performance of the models was evaluated by calculating the Dice score, coefficient of determination (R²), and the squared Pearson correlation coefficient (r²) between the true and derived GA lesion 1-year ROG.

Results:

The model using baseline and 6-month FAF images to predict GA lesion enlargement at 1.5 years had the best performance for the derived 1-year ROG. Mean Dice scores were 0.73, 0.68, and 0.70 in the training, validation, and test sets, respectively. The R² (0.77, 0.53, and 0.79) and r² (0.83, 0.61, and 0.79) showed similar trends across the 3 sets.

Conclusions:

These findings show the potential of using baseline and/or 6-month visit FAF images to predict 1-year GA ROG using a deep learning approach. This work could potentially help support decision-making in clinical trials and more informed treatment decisions in clinical practice.

Financial Disclosures:

Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

10

项与 Lampalizumab 相关的新闻（医药）

2025-12-15

·FierceBiotech

Aviceda geographic atrophy hopeful fails to top Astellas\' med in phase 2

Despite the fail, Aviceda still plans to test its lead asset in two sham-controlled phase 3 trials in 2026.\n Aviceda Therapeutics has hit a snag in its goal to deliver a new treatment for geographic atrophy (GA), an advanced form of dry age-related macular degeneration. The biotech’s lead asset, AVD-104, failed to beat Astellas’ Izervay (avacincaptad pegol) at slowing the rate of retina lesion growth, missing the primary endpoint of a phase 2 trial.The trial enrolled 300 patients with GA and treated them with monthly eye injections of either Izervay or AVD-104 at low or high doses.\"The study did not meet its primary endpoint, which was designed to assess non-inferiority,\" a company spokesperson told Fierce Biotech. \"No statistical differences in GA lesion growth rates were observed across the three study arms.\"AVD-104 led to no serious adverse events, Aviceda reported in a Dec. 15 release, with the most common side effect being eye floaters. AVD-104 is a nanoparticle adorned with polysialic acid, designed to bind to receptors on the surfaces of overactive immune cells like macrophages that cause eye inflammation in GA.Though it failed to top Izervay, AVD-104 did reduce the growth rate of GA lesions by 31% compared to previously published sham-treatment rates from Izervay’s phase 3 trial, according to Aviceda. The company described this finding as “clinically meaningful.” In addition, the company highlighted that patients given AVD-104 were able to read an average of 0.6 more letters in a visual acuity test after 12 months of treatment.“These results reinforce our belief that AVD-104 can provide meaningful functional vision benefit while reducing lesion progression, and has the potential to become a differentiated therapy addressing a significant unmet medical need for patients living with GA,” Aviceda CEO Jeffrey Nau, Ph.D., said in the release. Despite the failure, which Aviceda attributed to “imbalances in key baseline lesion characteristics across treatment arms,” the company still plans to test its lead asset in two sham-controlled phase 3 trials in 2026, according to the release. The Massachusetts-based biotech closed a $207.5 million series C in January to support its phase 3 vision.Aviceda was also testing the nanoparticle in a phase 2 trial for diabetic macular edema, but halted the study early due to “insufficient study drug supply and study funding constraints,” according to the clinicaltrials.gov database.GA has been a tough indication for pharma to crack. Roche blockbuster hopeful lampalizumab flopped in a critical phase 3 trial in 2017, with the Swiss pharma subsequently ditching the asset. Novartis scrapped its own GA candidate, acquired from Gyroscope Therapeutics, in September 2023 because of weak data.And in September 2024, Alkeus Pharmaceuticals reported that its oral candidate failed to reduce GA lesion growth in a phase 3 trial, with the company nevertheless declaring the results “clinically meaningful.”Apellis\' Syfovre (pegcetacoplan) was the first GA drug to break through, securing FDA approval in February 2023. However, the med was flagged by the agency for rare cases of severe eye inflammation that can lead to blindness just months later. Astellas picked up Izervay through the $5.9 billion acquisition of Iveric Bio in March 2023, garnering an approval of its own that August.Neither Izervay nor Syfovre is able to restore vision, and injections of both come with the risk of side effects like inflammation, bleeding and blurred sight.Outside of therapeutics, Science Corp. announced in October that its retinal implant was able to give GA patients some vision back in a clinical trial.Editor\'s note: This story was updated at 4:00 p.m. ET with a statement from Aviceda.

$Aviceda geographic atrophy hopeful fails to top Astellas\' med in phase 2$

临床3期并购临床2期上市批准临床结果

2025-12-07

·心研生信分析

整合多组学生信分析探究CD4+T细胞激活图谱解锁“糖心”密码：从免疫时序因果到精准靶点

今天小编给大家分享一篇发表于《Nature Communications》（IF=15.7，中科院1区）的文章：Transcriptome-wide Mendelian randomization during CD4+T cell activation reveals immune-related drug targets for cardiometabolic diseases。作者利用转录组和孟德尔随机化生信分析，系统评估了CD4+T细胞激活过程中11,021种基因表达谱对2型糖尿病和冠状动脉疾病的潜在因果效应，为免疫介导的心脏代谢病药物研发提供了新靶点。文章亮点： 1. 大规模转录组MR分析：研究采用孟德尔随机化方法，系统评估了11,021个基因在CD4+T细胞激活过程中的表达对2型糖尿病（T2D）和冠状动脉疾病（CAD）的因果影响，为免疫-代谢疾病机制提供遗传学证据。 2. 免疫特异性药物靶点发现：鉴定出162个T2D相关和80个CAD相关基因，其中12%-16%具有CD4+T细胞特异性，并筛选出25个已处于临床研究阶段的靶向基因（如LIPA/GCK），为心脏代谢疾病提供免疫介导的治疗新靶点。 3. 动态因果模式揭示：首次发现T细胞激活过程中存在时间依赖性因果效应（69个T2D基因对和34个CAD基因对），这些基因呈现8倍更高的遗传效应强度，阐明了免疫激活时序在疾病发生中的关键作用。（一）研究背景： 1型糖尿病已被确认为自身免疫病，FDA近期批准抗CD3单抗Teplizumab即其例证；而2型糖尿病传统归为代谢病，但越来越多证据显示慢性低度炎症、胰岛自身反应性T细胞浸润及CD4+/CD8+/Treg数量功能异常同样驱动β细胞衰竭，提示免疫-代谢交叉对话是T2D进展的关键环节。尽管IL-1βRa、TNF-α抑制剂等已显临床降糖获益，却缺乏系统筛查CD4+T细胞特异靶点的研究。单细胞测序技术可在T细胞激活的0 h–5天动态捕捉细胞状态特异性表达数量性状位点（dynamic eQTL），弥补既往bulk组织eQTL无法解析细胞异质性的缺陷。（二）研究意义：本研究首次整合动态单细胞eQTL与孟德尔随机化，系统评估11,021个基因表达谱在CD4+T细胞激活五时点中对T2D及冠状动脉疾病的因果效应，旨在：①揭示免疫基因驱动心脏代谢疾病的动态调控规律；②优先锁定具备免疫特异性的可成药靶点，为T2D/CAD的免疫干预提供遗传学证据与候选分子，缩短从机制到临床的转化路径。（三）研究结果： 3.1. 研究设计。 Figure 1 动态与非动态eQTL磁共振分析的研究设计。 3.2 利用与CD4+T细胞活化相关的动态eQTLs，以及来自四项研究的非动态eQTLs，研究基因表达对2型糖尿病和冠状动脉疾病的影响机制对11021个CD4+ T细胞激活时相表达谱行两样本MR，发现652对基因-T2D及197对基因-CAD具稳健因果与共定位证据（FDR<0.05，共定位概率>70%），分别对应150个T2D易感基因与62个CAD易感基因。 Figure 2. 动态CD4+T细胞eQTLs对2型糖尿病和冠状动脉疾病的影响机制的研究结果，以及相关关键靶基因的信息。单细胞整合七队列验证：162个MR筛得T2D基因中79个（49%）在病例 vs 对照差异表达，其中61个集中于CD4+T；STK17B在naïve CD4+T低表达与T2D风险降低同步，MR与表达双向印证。 Figure 3. 162个与2型糖尿病风险具有因果关系的基因的差异表达分析结果用OneK1K等4组非动态eQTL复现MR，158对T2D、77对CAD信号仍显著；其中21对(9%)仅在免疫细胞eQTL可见，如Lampalizumab靶基因CFD在记忆CD4+T 16h与TEM 5天特异关联T2D。 Figure 4. 对162个与T2D相关的基因以及80个与CAD相关的基因进行动态磁共振检测结果与非动态磁共振检测结果的比较分析。 3.3 CD4+T细胞基因表达对2型糖尿病和冠状动脉疾病的细胞类型特异性影响。 46种CD4+T表达谱中39个与T2D、35个与CAD呈MR+共定位证据，信号富集于TCM、TEM亚群。DICE验证：96%T2D基因、91%CAD基因在CD4+T表达；其中14%T2D、10%CAD基因具T细胞特异性，12–16%的eQTL仅见于CD4+T，凸显细胞类型专一性。 Figure 5. 特定细胞类型的分析结果。 3. 4 在CD4+T细胞被激活的过程中，基因表达对2型糖尿病和冠状动脉疾病的具体影响动态eQTL揭示：149个（67%）T2D/CAD因果基因仅在CD4+T激活态显效，MRPL21、GCDH、HLA-C等效应峰值分别位于40h或16h；时序分析更锁定31对基因-疾病具激活时点特异因果，其获稳健MR证据的概率提高8-9倍。 Figure 6. 不同激活时间点下，基因分布情况、成对Z分数值以及MR估计值的异质性检验结果。 (四) 研究结论总之，这项研究确定了162个可能与2型糖尿病相关的致病基因，以及80个可能与冠状动脉疾病相关的致病基因；其中，有9%的这些基因-疾病对应关系仅能通过针对特定免疫细胞的eQTL分析才能被识别出来。通过对不同细胞类型及特定激活时间点下的基因表达情况进行分析，我们进一步加深了对2型糖尿病与冠状动脉疾病相关基因表达模式的理解。我们的研究强调了探索免疫途径与代谢途径之间相互关联性的重要性，为开发针对心血管代谢性疾病的免疫调节药物奠定了基础。

免疫疗法临床研究

2025-09-19

·EndPoints

The Endpoints 11: At Third Arc, a small team with major league talent tackles some big disease targets

Some biotechs stand out because of their novel scientific promise. Others gain a prominent profile because of the clear commitment of savvy investors with a record of picking the best startup bets. And then you have standouts that boast of deep experience in the management group. At Third Arc Bio, the science isn’t particularly novel. But the team running the company has levels of experience rarely seen in the freshman class of companies. And the investors clearly believe these players can leverage that know-how to make their mark with a new generation of therapies for solid tumors — while also pushing into the flip side of autoimmune disease. “The concept is fairly straightforward,” CEO Peter Lebowitz said. “The execution of that concept is complex.” In order to get T cells activated to kill, you need two signals, he explains. Signal one, the T cell receptor, is engaged by CD3. In hematological malignancies, CD3 works well alone because the malignancies have a costimulatory signal built in. But solid tumors require another signal. So for their lead program, now in Phase 1, Third Arc selected CD28 to be the second signal that will let them tackle solid tumors. Lebowitz, who led Johnson & Johnson’s oncology R&D through a groundbreaking alliance with China’s Legend on the CAR-T drug Carvykti, relied on his experience to reach the conclusion that Third Arc is a solid bet. He also trusts the expertise of chief scientific officer and founder Sanjaya Singh, who adds another 25-plus years on the experience side. That wide-ranging background includes key roles in inventing Skyrizi as well as lampalizumab and other drugs, across a career at J&J and Boehringer Ingelheim. They have both been there and done that. Then there’s Joe Erhardt and Debi Watson, two more J&J vets running clinical development and business ops. The leadership team in a staff of 37 is augmented by dozens more working at a contract operation in India, where Singh got his PhD at Banaras Hindu University before completing his postdoc at MD Anderson Cancer Center. A lot of people know how to make a good molecule, Singh said. But it’s the execution — finding the best in a mix of factors — that separates the big new drugs from the also-rans. And that’s where he believes the Third Arc team will come out ahead. The first target up is Claudin-6. “If you choose targets carefully where you don’t have overlap of expression in the tissue and having a good second signal that is controlled, you can also increase the specificity on the target,” Singh said. And that translates to greater potency and a new generation of more effective drugs. Launched three years ago, Third Arc is betting that it can efficiently line up the kind of human data that keeps people interested in their future. In oncology, it’s possible to garner that kind of attention in an early stage, as you map out just how long it would take to get an approval — either full or accelerated. And despite the headlines, Lebowitz said, he’s so far seen little disruption at the FDA that would interfere with that plan. Third Arc got a $165 million launch round early this year, a mega-raise led by Vida Ventures, which is designed to push ahead to 2027 and several clinical programs. That’s solid funding, but not the same kind of resources that a multinational like J&J can bring to the table. “The scale is different,” Lebowitz said, “but the issues are very similar.” They are: When Singh set out to create the company in 2022, he had Omega Funds — where he’s a venture partner — in his corner and a support team he could rely on in India that allowed him to go it alone as the sole full-timer for a few months. And while remaining small, Third Arc will continue to employ a global strategy as it jockeys drugs into the clinic. “I’ve always looked at drug development as a global thing,” Lebowitz said. And if you have the right kind of experience, that can be just as important in a small organization as it is in a large one.

临床1期

100 项与 Lampalizumab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10440	Lampalizumab	-	DB11826

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
年龄相关性黄斑变性	临床3期	美国	Hoffmann-La Roche, Inc.	2014-09-18
年龄相关性黄斑变性	临床3期	阿根廷	Hoffmann-La Roche, Inc.	2014-09-18
年龄相关性黄斑变性	临床3期	澳大利亚	Hoffmann-La Roche, Inc.	2014-09-18
年龄相关性黄斑变性	临床3期	奥地利	Hoffmann-La Roche, Inc.	2014-09-18
年龄相关性黄斑变性	临床3期	比利时	Hoffmann-La Roche, Inc.	2014-09-18
年龄相关性黄斑变性	临床3期	加拿大	Hoffmann-La Roche, Inc.	2014-09-18
年龄相关性黄斑变性	临床3期	丹麦	Hoffmann-La Roche, Inc.	2014-09-18
年龄相关性黄斑变性	临床3期	法国	Hoffmann-La Roche, Inc.	2014-09-18
年龄相关性黄斑变性	临床3期	德国	Hoffmann-La Roche, Inc.	2014-09-18
年龄相关性黄斑变性	临床3期	匈牙利	Hoffmann-La Roche, Inc.	2014-09-18

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02503332 \| NCT01527500 \| NCT02247531 \| NCT04465955 \| NCT03815825 \| NCT01229215 \| NCT05019521 \| NCT04643886 \| NCT02247479 \| NCT04566445 \| NCT02515942 \| NCT02686658 \| NCT04435366 \| NCT05230537 \| NCT04437368 \| NCT03525600 \| NCT00935883 \| NCT04656561 \| NCT03525613 (Pubmed \| Cochrane Database Syst Rev)	N/A	年龄相关性黄斑变性	4,052	Intravitreal lampalizumab	獵簾蓋夢醖餘夢壓鹹夢(醖觸顧壓製醖積範鑰餘) = Progression to MNV or exudative AMD is a possible emergent adverse event of complement inhibition, requiring careful consideration should these agents be used clinically 願壓遞築繭繭衊蓋夢製 (憲範觸鏇鏇糧艱網餘顧 ) 更多	-	2023-06-14
				Intravitreal pegcetacoplan
NCT02247479 (post hoc analysis of 2 clinical trials investigating the IOP safety of intravitreous lampalizumab on geographic atrophy secondary to age-related macular degeneration \| Chroma and Spectri \| CHROMA, CTgov)	临床3期	年龄相关性黄斑变性 \| 地图样萎缩	906	Sham	鬱壓顧範艱憲衊積夢蓋(窪壓願襯範積憲醖範範) = 願網顧憲糧膚鹽膚鏇鹹獵夢壓衊鹹憲醖鬱鬱廠 (淵蓋網窪糧衊觸鹹夢憲, 0.066) 更多	-	2019-04-23
NCT02247531 (post hoc analysis of 2 clinical trials investigating the IOP safety of intravitreous lampalizumab on geographic atrophy secondary to age-related macular degeneration \| Chroma and Spectri \| SPECTRI, CTgov)	临床3期	年龄相关性黄斑变性 \| 地图样萎缩	975	Sham Comparator	蓋願淵獵鹹遞餘鑰衊繭(膚顧餘顧膚觸餘獵網願) = 願壓繭壓齋範醖膚積顧鬱積顧艱憲積願獵糧膚 (鬱鹽齋鹹遞鏇衊獵衊壓, 0.056) 更多	-	2019-03-14
NCT01602120 (CTgov)	临床2期	地图样萎缩	159	Lampalizumab (CFD4870g Sham)	蓋淵衊繭鏇觸鑰選窪衊 = 淵獵鏇構餘衊繭鏇構願鏇製窪衊夢選鏇製選廠 (鑰網糧膚選鏇鏇鹹觸選, 壓艱膚繭顧製獵窪顧築 ~ 鏇窪製艱襯艱齋艱醖築) 更多	-	2019-02-21
				Lampalizumab (CFD4870g Lampalizumab)	蓋淵衊繭鏇觸鑰選窪衊 = 觸選構壓鹽衊簾醖簾鹹鏇製窪衊夢選鏇製選廠 (鑰網糧膚選鏇鏇鹹觸選, 獵鹽餘鑰獵壓艱艱願鹹 ~ 觸淵廠製鑰網襯齋夢積) 更多
NCT02745119 (CTgov)	临床3期	年龄相关性黄斑变性 \| 地图样萎缩	994	Lampalizumab (Lampalizumab Q4W - Treatment-Naive)	網糧網襯窪醖醖廠願鬱 = 獵鹽簾襯鏇遞範觸憲遞網觸製艱顧窪廠製遞醖 (壓積顧鏇窪築壓艱網鬱, 觸鏇網網餘窪鹽襯簾網 ~ 繭餘顧構範夢蓋夢鏇憲) 更多	-	2019-02-15
				Lampalizumab (Lampalizumab Q4W - Previously Treated)	網糧網襯窪醖醖廠願鬱 = 遞選艱鹽選積齋廠鑰齋網觸製艱顧窪廠製遞醖 (壓積顧鏇窪築壓艱網鬱, 鹹憲積壓選廠願醖顧蓋 ~ 鹹艱積鹽遞窪網構鏇餘) 更多
NCT02247479 \| NCT02247531 (Chroma and Spectri, ARVO2018)	临床3期	年龄相关性黄斑变性 complement factor I (CFI)-profile	-	Lampalizumab every 4 weeks	觸廠艱鑰壓願鬱範淵鹹(網憲鹽遞構艱繭網艱築) = 衊廠淵遞艱餘憲壓夢簾構鏇淵網鏇鑰鹹糧鏇鹽 (壓鹹齋簾憲獵衊鑰遞鹽 )	不佳	2018-07-01
				Lampalizumab every 6 weeks	觸廠艱鑰壓願鬱範淵鹹(網憲鹽遞構艱繭網艱築) = 願鑰膚餘鬱壓繭鹹鹽繭構鏇淵網鏇鑰鹹糧鏇鹽 (壓鹹齋簾憲獵衊鑰遞鹽 )
NCT02247479 \| NCT02247531 (Chroma and Spectri, Pubmed \| JAMA Ophthalmol)	临床3期	年龄相关性黄斑变性	1,881	Lampalizumab 10 mg every 4 weeks	廠憲蓋糧糧醖糧築製鑰(糧糧膚築遞膚衊鬱獵積) = Endophthalmitis occurred after 5 of 12,447 injections (0.04%) or in 5 of 1,252 treated participants (0.4%) through week 48 願構獵鹽醖鹹窪糧廠淵 (鬱簾構鹹窪選繭廠簾積 )	不佳	2018-06-01
				Lampalizumab (Sham procedure every 4 weeks)
MAHALO (ARVO2015)	临床2期	地图样萎缩	100	Lampalizumab	鹹醖齋網構艱淵鏇餘衊(襯壓鏇獵顧製醖構壓願) = 選窪餘範築淵醖鹹鏇艱範壓網糧築簾願鹽齋網 (顧壓糧齋齋鹽構鹽範繭 )	-	2015-06-01
				Sham	鹹醖齋網構艱淵鏇餘衊(襯壓鏇獵顧製醖構壓願) = 觸蓋獵繭獵選選憲觸鹹範壓網糧築簾願鹽齋網 (顧壓糧齋齋鹽構鹽範繭 )
NCT01229215 (MAHALO study, ARVO2014)	临床1/2期	年龄相关性黄斑变性	143	Lampalizumab	夢襯鬱壓鹹窪憲鏇遞積(窪夢獵蓋窪獵獵鑰遞衊) = 襯繭製夢製簾夢遞醖鹽願齋鏇膚築獵網鹹範網 (鹽觸獵夢艱遞窪構艱獵, 7.69)	-	2014-04-01